Welcome to our dedicated page for ZEO ScientifiX SEC filings (Ticker: ZEOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ZEO ScientifiX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ZEO ScientifiX's regulatory disclosures and financial reporting.
Zeo ScientifiX, Inc. reported the initial holdings of its Chief Science Officer, David John Kisiday, in a Form 3. He beneficially owns 50,000 shares of common stock, all in the form of restricted stock granted on January 23, 2026 under the company’s 2021 Equity Incentive Plan.
The grant vests over two years, with 20,000 shares vesting on the first anniversary of Mr. Kisiday’s employment agreement effective January 23, 2026 and 30,000 shares vesting on the second anniversary. Vesting is contingent on his continued service and the other terms of the incentive plan.
Zeo ScientifiX, Inc. (ZEOX) is a clinical-stage biopharmaceutical company focused on regenerative medicine and degenerative disease therapies. Its lead products, including Zofin™ and Patient Pure X™ (PPX™), use birth-tissue and blood-derived nanoparticles manufactured in FDA-registered, cGMP-compliant labs.
The company is repositioning around Florida’s new stem cell law SB 1768, which permits certain non-FDA-approved stem cell treatments for orthopedic, wound care, and pain indications. Zeo plans to leverage this framework to grow revenue, collect real‑world data, and advance clinical programs at lower cost.
Zeo reported a net loss of $5,521,000 for the year ended October 31, 2025, with an accumulated deficit of $67,734,000 and a working capital deficit of $1,915,000. Auditors raised substantial doubt about its ability to continue as a going concern. The company is pursuing partnerships, acquisitions, international sales, and a broad patent and trademark portfolio to support future growth amid significant FDA and funding risks.
Zeo ScientifiX, Inc. appointed Dr. John D. Kisiday as Chief Science Officer effective January 23, 2026. He brings nearly 30 years of experience in tissue engineering and regenerative medicine, including work with cell-based, biomaterial and drug-based orthopedic therapies and extensive academic research leadership.
Under an employment agreement effective the same date, Dr. Kisiday receives a $175,000 base salary and a 50,000-share stock grant under the 2021 Incentive Plan, vesting 20,000 shares after one year and 30,000 shares after two years, contingent on continued employment. His role is at-will and includes a tenure-based severance formula for termination without cause or for good reason, plus customary confidentiality, non-compete and non-solicitation covenants.
Zeo ScientifiX, Inc. awarded equity incentives to two senior executives. On January 14, 2026, the company granted 175,000 restricted shares of common stock under its 2021 Incentive Stock Plan to each of Ian Bothwell, who serves as Chief Executive Officer, Chief Financial Officer and director, and Dr. George Shapiro, the Chief Medical Officer and a director. These restricted shares are designed to vest over time, with 50% vesting on the eighth-month anniversary of the award date and the remaining 50% vesting on the one-year anniversary. This structure encourages ongoing service and aligns the executives’ interests with the company’s long-term performance.
Zeo ScientifiX, Inc. reported an insider equity award involving Greyt Ventures, LLC, a 10% owner. On January 14, 2026, Greyt Ventures received 175,000 shares of Zeo ScientifiX common stock as a grant of restricted shares at a stated price of $0 per share under the company’s 2021 Equity Incentive Plan.
The restricted shares vest in two equal tranches: 50% on the eighth-month anniversary of the grant date and the remaining 50% on the twelfth-month anniversary. Following this grant, Greyt Ventures indirectly beneficially owned 425,000 shares of Zeo ScientifiX common stock. The filing notes these securities were issued to Greyt Ventures, LLC, which is owned by a trust for which Ms. Wendy Grey serves as trustee.
Zeo ScientifiX, Inc. reported an insider equity award for its CEO, CFO and director Ian T. Bothwell. On 01/14/2026, he received 175,000 shares of common stock at a price of $0 per share as a grant of restricted stock under the company’s 2021 Equity Incentive Plan. These shares vest in two equal parts, with 50% vesting on the 8th month anniversary of the grant date and the remaining 50% vesting on the 12th month anniversary. Following this transaction, Bothwell beneficially owned 915,094 shares of Zeo ScientifiX common stock held directly.
Zeo ScientifiX, Inc. reported that Chief Medical Officer and director George Craig Shapiro received a grant of 175,000 shares of common stock on 01/14/2026. The filing shows this as an acquisition at a price of $0 per share, reflecting a restricted stock award under the company’s 2021 Equity Incentive Plan.
According to the terms, the restricted shares vest 50% on the 8th month anniversary of the grant date and the remaining 50% on the 12th month anniversary. Following this equity grant, Shapiro beneficially owns 578,021 shares of Zeo ScientifiX common stock in direct ownership.
Zeo ScientifiX, Inc. reported that it has entered into a comprehensive strategic partnership with Cytora Therapeutics Ltd. and Made Scientific, Inc. The collaboration focuses on advancing and commercializing Cytora’s novel allogeneic, off-the-shelf human oral mucosal stem cell therapy in the United States.
Cytora is described as a clinical-stage biotechnology company based in Israel, while Made Scientific is a U.S.-based cell therapy contract development and manufacturing organization. The joint press release outlining additional details of the partnership is attached as Exhibit 99.1.
Zeo ScientifiX, Inc. announced a leadership change, making Ian T. Bothwell the company’s full-time Chief Executive Officer effective December 24, 2025. He had been serving as Interim Chief Executive Officer while also holding the role of Chief Financial Officer, and will continue in the dual position of Chief Executive Officer and Chief Financial Officer. This move formalizes the company’s executive leadership structure by confirming Bothwell as permanent CEO.
Zeo ScientifiX, Inc. reported that, effective November 30, 2025, it terminated the employment of Ron Borsheim as its Chief Sales Officer – Aesthetics. The company identifies itself as a Nevada corporation with principal offices in Davie, Florida, and it currently has no securities listed on a national securities exchange. The report is signed by Interim Chief Executive Officer and Chief Financial Officer Ian T. Bothwell, indicating executive-level oversight of this leadership change.